Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004 - 2011

Turkish Journal of Medical Sciences

Volumn 43, Issue 4, 2013, Pages 537-541

  Pullukçu, Hüsnü ^a   Aydemir, Şöhret ^a   Işikgöz Taşbakan, Meltem ^a   Sipahi, Oǧuz Reşat ^a   Çilli Hall Jr , Feriha ^a   Tünger, Alper ^a  

^a Department of Infectious Diseases and Clinical Microbiology ^*  (Turkey)

Author keywords

Fosfomycin; Resistance; Urinary tract infection

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; NONHUMAN; PROSPECTIVE STUDY; STRAIN DIFFERENCE; URINALYSIS;

EID: 84880958756     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1210-75     Document Type: Article

References (23)

1. Coskun Ö, Erdem H, Avci A. Management of communityacquired acute bacterial cystitis in Turkey. Turk J Med Sci 2011; 41: 149-57.
2. Pullukçu H, Aydemir S, Tasbakan MI, Çilli F, Tunger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase producing Esherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim sulfamethoxazole. Turk J Med Sci 2008; 38: 175-80.
3. Tasbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem infeksiyonlarindan soyutlanan Escherichia coli suslarina fosfomisinin in-vitro etkinliginin diger antibiyotiklerle karsilastirilmasi. ANKEM Derg 2004; 18: 216-9 (in Turkish).
4. Pullukçu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.
5. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamaseproducing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010; 22: 355-7.
6. Clinical and Laboratory Standards Institute. 2011 Antimicrobial Susceptibility Testing Update. Wayne, PA, USA: CLSI; 2011. Available at http://www.clsi.org/Content/NavigationMenu/ Education/Teleconferences/Feb232011.htm.
7. Yasar KK, Pehlivanoglu F, Sengöz G. Alternatif tedavi seçenegi olraka fosfomisinin komplike üriner sistem infeksiyonlarindan izole edilejn GSBL pozitif Escherichia coli suslarina etkinligi. ANKEM Derg 2011; 25: 12-6 (in Turkish).
8. Mengeloglu FZ, Demircan F, Oduncu MK. Idrar kültürlerinden soyutlanan Escherichia coli izolatlarinin fosfomisine karsi invitro duyarliliklarinin degerlendirilmesi. ANKEM Derg 2011; 25: 99-102 (in Turkish).
9. Bayram Y, Eren H, Berktas M. Idrar örneklerinden izole edilen bakteriyel patojenlerin dagilimi ve GSBL pozitif ve negatif Escherichia coli suslarinin fosfomisin ve diger antimikrobiyallere duyarlilik paterni. ANKEM Derg 2011; 25: 232-6 (in Turkish).
10. Deveci Ö, Yula E, Özer TT, Tekin A. Üriner sistem infeksiyonlarindan izole edilen Escherichia coli suslarina fosfomisin trometamolün ve bazi antibiyotiklerin in-vitro etkinligi. Dicle Tip Dergisi 2011; 38: 298-300 (in Turkish).
11. Ceran N, Mert D, Koçdogan FY, Erdem I, Adalati R, Ozyurek S et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 2010; 16: 424-30.
12. Hosbul T, Ozyurt M, Baylan O, Bektöre B, Ardiç N, Ceylan S et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul 2009; 43: 645-9.
13. Uyanik H, Hanci H, Yazgi. Üriner sistem infeksiyonlarindan soyutlanan toplum kökenli Escherichia coli suslarina fosfomisin trometamolün ve bazi antibiyotiklerin in-vitro etkinligi. ANKEM Derg 2009; 23: 172-6 (in Turkish).
14. Asik G, Çiftçi IH, Aktepe OC, Çetinkaya Z, Altindis M. In vitro activity of fosfomycin against extended spectrum-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae strains. Turk J Immunol 2008; 13: 1-4.
15. Akyar I. Antibiotic resistance rates of extended spectrum betalactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital. Mikrobiyol Bul 2008; 42: 713-5.
16. Tekin A, Deveci Ö, Dal T, Tekin R, Özekinci T, Dayan S. Üropatojen Escherichia coli izolatlarina fosfomisin ve bazi antibiyotiklerin in vitro etkinligi. ANKEM Derg 2012; 26: 61-8 (in Turkish).
17. Pullukçu H, Aydemir S, Isikgöz Tasbakan M, Sipahi OR, Çilli F, Ulusoy S. In vitro efficacy of nitrofurantoin on Escherichia coli strains isolated from urine cultures. Turk J Infect 2007; 21: 197-200.
18. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended spectrum B-lactamase-producing Escherichia coli related lower urinary tract infection. Int J Antimicrob Agents 2012; 40: 554-56.
19. Arman D, Agalar C, Dibay M, Tunçcan ÖG, Keten DT, Aygün G et al. Community acquired lower urinary tract infections in primary care: causative agents and antimicrobial susceptibility. J Infect Microb Antimicrob 2012; 1: 10.
20. Isikgöz Tasbakan M, Pullukçu H, Sipahi OR, Yamazhan T, Arda B, Ulusoy S. A pooled analysis of the resistance patterns of Escherichia coli strains isolated from urine cultures in Turkey: a comparison of the periods 1997-2001 and 2002-2007. Turk J Med Sci 2011; 41: 557-64.
21. Özcan L, Yilmaz S, Pekdemir M, Yaka E. Akut nonkomplike Alt üriner sistem enfeksiyonu olan hastalarda fosfomisintrometamol ve siprofloksasinin etkinliginin karsilastirilmasi. Tr J Emerg Med 2011; 11: 104-9 (in Turkish).
22. Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul 2010; 44: 311-21.
23. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67: 255-68.